Category: ProMIS Neurosciences

PROMIS NEUROSCIENCES TO PRESENT AT HC WAINWRIGHT INVESTOR CONFERENCE

TORONTO, Ontario and CAMBRIDGE, Mass. —September 3, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its participation in the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC.  The …

Continue reading

PROMIS NEUROSCIENCES APPOINTS INTERNATIONALLY RECOGNIZED RESEARCHER IN ALZHEIMER’S DISEASE IN DOWN SYNDROME DR. ANDRE STRYDOM TO ITS SCIENTIFIC ADVISORY BOARD

TORONTO, Ontario and CAMBRIDGE, Mass.—August 27, 2019—ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has added Dr. Andre Strydom to its scientific advisory board (SAB). Dr. Strydom is a world-recognized expert in ageing-related issues …

Continue reading

PROMIS NEUROSCIENCES ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS

TORONTO, ON. and CAMBRIDGE, MA. – July 24, 2019 – ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases,  today announced the voting results of the Corporation’s annual meeting of shareholders held on June 27, …

Continue reading

PROMIS NEUROSCIENCES HIGHLIGHTS DATA FOR PMN310 AT AAIC 2019

TORONTO, Ontario and CAMBRIDGE, Mass. —July 18, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data today for its lead clinical candidate, PMN310 for Alzheimer’s disease, at the annual Alzheimer’s Association International …

Continue reading

PROMIS NEUROSCIENCES TO PRESENT DATA AT 2019 ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE

TORONTO, Ontario and CAMBRIDGE, Mass. —July 10, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give an oral presentation on its lead clinical candidate, PMN310 for Alzheimer’s disease, at the annual Alzheimer’s …

Continue reading